On 25 February 2020, the first patient diagnosed with COVID-19 in Catalonia was admitted to the Intensive Care Unit at the Hospital Clínic de Barcelo1
The aim is to vaccinate as many professionals as possible as quickly as possible.
The biotechnological pharmaceutical company HIPRA has received authorization from the Spanish Agencyfor Medicines and Health Products (AEMPS) to sta1
The results show that people with HIV with chronic comorbidities and an unsuppressed HIV viral load could be at greater risk of developing severe COV1
Researchers from the CLÍNIC-IDIBAPS, the Hospital Universitari Vall d’Hebron and the Parc Taulí de Sabadell have shown the damage caused by the SARS-1
Since the start of the vaccination campaign, there has been a significant reduction in severe cases of COVID-19. Nevertheless, some fully vaccinated1
This week the vaccine began to be administered to the first volunteers participating in Phase I/IIa of the trial at the Hospital Trueta in Girona and1
Interview with Dr. Eduard Vieta, Head of the Psychiatry and Psychology Service
HIPRA (Amer, Girona) is looking for volunteers aged between 18 and 39 who have not received any COVID-19 vaccine and who have not had the infection,1
The Hospital Clínic de Barcelona has advised the Festival Castell de Peralada, which starts this Friday, on the application of COVID-19 prevention me1
